top of page

Oral mRNA vaccine progress stalls


A project to deliver mRNA vaccines in oral form will not go ahead following an early-stage study in mice.


BioNTech, the German company that has successfully developed mRNA vaccines for Covid-19, has been looking for a way to deliver mRNA vaccines orally since last year, using a technology developed by Matinas Biopharma.


To test whether the vaccine worked in mice, Matinas used a formulation to ‘handle the complexity and frailty of mRNA’, but it said the approach did not show any activity in the animals, despite working in cell studies.


A recent PLOS article has looked at the progress of other intranasal and oral vaccines for Covid-19, highlighting their rapid development and authorisation in numerous ongoing clinical trials.


End

Comments


bottom of page